Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 8/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DCK | P27707 | 2/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065400 | 0.84 | IKBKB (0.44) | MITFHTTPAX8PIP4K2C | |
| SCHEMBL5064749 | 0.84 | MAPT (0.49) | ADORA3MITFHTTPIP4K2CKDM4E | |
| SCHEMBL5064698 | 0.81 | PIK3CD (0.38) | ADORA3KDM4E | |
| SCHEMBL14031769 | 0.80 | MAPT (0.46) | HTTPIP4K2C | |
| SCHEMBL14031774 | 0.76 | PIK3CD (0.34) | ADORA3 | |
| SCHEMBL1693615 | 0.76 | PIK3CD (0.43) | ADORA3HTTPIP4K2CKDM4E | |
| SCHEMBL5064310 | 0.74 | PIK3CD (0.42) | ADORA3KDM4E | |
| SCHEMBL13801078 | 0.74 | ADORA3 (0.56) | ADORA3TRPM8KDM4EDCK | |
| SCHEMBL5064152 | 0.72 | PIK3CD (0.40) | ADORA3 | |
| SCHEMBL4796320 | 0.70 | TEK (0.72) | HTTPIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1731523-A1 | THIAZOLOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | FGFR3, FGFR1, ERBB3 | ADORA3 274/4885TRPM8 1192/4885MITF 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.